|
| Any of the following criteria excluded subjects from study participation: |
|
1 | Having a significant acute or chronic coexisting illness (cardiovascular, endocrine, immunological, metabolic, or any condition which contraindicates, in the investigator’s judgment, entry into the study). |
2 | Having a diagnosis of inflammatory bowel disease, bowel cancer, coeliac disease, or any other bowel disease, which, in the opinion of the investigator, makes them unsuitable for entry into the study. |
3 | Any GI-related abdominal surgery other than hernia repair or appendectomy. Cholecystectomy more than 6 months previously is not an exclusion. |
4 | Individuals who have taken any antibiotics or oral steroids in the last 3 weeks. |
5 | Individuals planning to start any new medications during the course of the study |
6 | Known HIV infection, or hepatitis A, B, or C active infection. |
7 | Change in dose or introduction of an antipsychotic within the last month. |
8 | Have suffered from an uncontrolled or current major psychiatric disorder. |
9 | Individuals who, in the opinion of the investigator, are poor attendees or unlikely for any reason to be able to comply with the study requirements. |
10 | Subject is currently enrolled in or has not yet completed at least 30 days since ending another investigational device or drug study(s), or the patient is receiving another investigational agent(s). |
11 | Females who are pregnant or breastfeeding. |
12 | Unwilling or unable to comply with the study procedures. This includes leaving at least one hour between the ingestion of silicolgel and any other medication. |
13 | Taking a probiotic supplement and being unwilling to leave at least 1 hour between ingestion of IP and probiotic. |
14 | History of regular use of silicolgel or enterosgel for IBS. |
|